We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+15.35%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$370M
AUM Growth
+$95.8M
(+35%)
Cap. Flow
+$47.5M
Cap. Flow
% of AUM
12.83%
Top 10 Holdings %
Top 10 Hldgs %
36.28%
Holding
91
New
23
Increased
27
Reduced
13
Closed
22
Avg Time Held Equity + Options
1.6
quarters
Top 10 Avg Time Held Equity + Options
0.6
quarters
Top 20 Avg Time Held Equity + Options
0.9
quarters
Avg Time Held Equity only
1.8
quarters
Top 10 Avg Time Held Equity only
0.6
quarters
Top 20 Avg Time Held Equity only
1
quarter
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$24.7M |
| 2 |
CVS Health
CVS
|
+$13.7M |
| 3 |
GSK
GSK
|
+$10.5M |
| 4 |
Gilead Sciences
GILD
|
+$9.94M |
| 5 |
Globus Medical
GMED
|
+$9.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$9.96M |
| 2 |
Cigna
CI
|
+$9.92M |
| 3 |
Cardinal Health
CAH
|
+$9.32M |
| 4 |
CELG
Celgene Corp
CELG
|
+$6.56M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$6.31M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.37% |
| 2 | Miscellaneous | 11.53% |
| 3 | Industrials | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CVS Health
CVS
$112B
| $19.8M | 5.34% |
367,071
+222,294
| +154% | +$13.7M |
2018 Q4
1 quarter
|
|
|
2
Biogen
BIIB
$33.8B
| $18.6M | 5.02% |
+78,596
| New | +$24.7M |
2019 Q1
0 quarters
|
|
|
3
Gilead Sciences
GILD
$183B
| $16M | 4.32% |
245,968
+149,488
| +155% | +$9.94M |
2018 Q4
1 quarter
|
|
4
HCA Healthcare
HCA
$99.8B
| $14M | 3.78% |
107,428
+39,389
| +58% | +$5.29M |
2018 Q1
4 quarters
|
|
5
Medtronic
MDT
$119B
| $12M | 3.23% |
131,464
+349
| +0.3% | +$31.2K |
2018 Q3
2 quarters
|
|
|
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $11.2M | 3.03% |
766,980
+323,571
| +73% | +$3.72M |
2018 Q4
1 quarter
|
|
|
7
GSK
GSK
$92.7B
| $10.9M | 2.96% |
+209,600
| New | +$10.5M |
2019 Q1
0 quarters
|
|
8
Medpace
MEDP
$17B
| $10.7M | 2.9% |
181,866
+118,686
| +188% | +$7.09M |
2018 Q4
1 quarter
|
|
9
Ascendis Pharma A/S
ASND
$14.7B
| $10.6M | 2.87% |
+90,325
| New | +$7.91M |
2019 Q1
0 quarters
|
|
|
GWPH
10
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $10.5M | 2.83% |
62,186
-22,000
| -26% | -$3.27M |
2018 Q4
1 quarter
|
|
11
PUT
DELISTED
Walgreens Boots Alliance
WBA
| $10.5M | 2.83% |
+165,500
| New | +$11.3M |
2019 Q1
0 quarters
|
|
|
12
Globus Medical
GMED
$10.2B
| $10M | 2.71% |
+202,827
| New | +$9.18M |
2019 Q1
0 quarters
|
|
13
Emergent Biosolutions
EBS
$354M
| $9.1M | 2.46% |
180,156
+106,363
| +144% | +$6.27M |
2018 Q3
2 quarters
|
|
|
GWPH
14
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $8.56M | 2.31% |
+50,800
| New | +$7.56M |
2019 Q1
0 quarters
|
|
15
Novo Nordisk
NVO
$168B
| $8.47M | 2.29% |
324,000
+29,244
| +10% | +$719K |
2018 Q4
1 quarter
|
|
16
Viking Therapeutics
VKTX
$3.39B
| $8.47M | 2.29% |
852,160
+215,114
| +34% | +$1.8M |
2017 Q4
5 quarters
|
|
|
17
Alnylam Pharmaceuticals
ALNY
$29.9B
| $7.4M | 2% |
79,153
-75,484
| -49% | -$6.31M |
2018 Q2
3 quarters
|
|
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.36M | 1.99% |
530,175
+360,918
| +213% | +$4.13M |
2018 Q4
1 quarter
|
|
19
Lite Strategy Inc
LITS
$36.8M
| $7.24M | 1.95% |
117,832
-860
| -0.7% | -$49.3K |
2017 Q4
5 quarters
|
|
20
Sanofi
SNY
$93.7B
| $6.95M | 1.88% |
156,854
-111,534
| -42% | -$4.78M |
2018 Q1
4 quarters
|
|
21
Molina Healthcare
MOH
$10.9B
| $6.38M | 1.72% |
44,928
+2,059
| +5% | +$278K |
2018 Q4
1 quarter
|
|
22
McKesson
MCK
$112B
| $6M | 1.62% |
51,300
+4,770
| +10% | +$589K |
2018 Q4
1 quarter
|
|
|
SPPI
23
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $5.92M | 1.6% |
+554,019
| New | +$5.93M |
2019 Q1
0 quarters
|
|
|
WCG
24
DELISTED
Wellcare Health Plans, Inc.
WCG
| $5.79M | 1.56% |
+21,459
| New | +$5.54M |
2019 Q1
0 quarters
|
|
25
PUT
Intuitive Surgical
ISRG
$149B
| $5.65M | 1.53% |
+29,700
| New | +$5.28M |
2019 Q1
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Sio Capital Management held 91 positions worth $370M, up 35% from $275M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sio Capital Management deployed $47.5M of net new capital in Q1 2019, opening 23 new positions and adding to 27 existing holdings. Its largest new stake was Biogen: 78,596 shares worth $18.6M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $6.31M trimmed.
- Sio Capital Management's largest Q1 2019 buy was Biogen: 78,596 shares worth $18.6M.
- Sio Capital Management added most to CVS Health in Q1 2019, an estimated $13.7M increase.
- Sio Capital Management's biggest Q1 2019 reduction was Alnylam Pharmaceuticals, cutting an estimated $6.31M.
- Sio Capital Management fully exited Cencora in Q1 2019, selling an estimated $9.96M.
- Sio Capital Management's ten largest holdings make up 36% of its $370M portfolio in Q1 2019.
- Sio Capital Management opened 23 new positions and closed 22 in Q1 2019.
- Sio Capital Management's portfolio value rose 35% quarter-over-quarter to $370M.
Based on Sio Capital Management's 13F filing for Q1 2019, filed 15 May 2019.